SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology and rare disease pipeline, while also tracking high short interest that has fueled speculation of a potential short squeeze.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating whether its aggressive acquisition strategy and high short interest signal an impending rebound or further downside following heavy share dilution. The community is sharply divided, with bulls pointing to the company's expanding backlog and defense partnerships, while vocal critics are focused on insider selling and the stock's poor recent performance.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending due to significant institutional accumulation and the building momentum surrounding the Agility Robotics commercialization narrative. Community sentiment remains focused on the potential for a major re-rating as investors compare the firm's strategic industrial partnerships to successful past robotics and infrastructure plays.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is seeing heightened community engagement driven by anticipation of a potential buyout, as investors weigh the impact of recent product approvals and the company's aggressive pipeline development in the GLP-1 adjunct space. While bullish participants point to valuable clinical assets as prime acquisition targets, others remain focused on navigating volatility and debating the impact of management's confrontational regulatory strategy on future valuation.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit share price slide represents a structural breakdown or a deep-value accumulation opportunity following an accelerated share buyback and cautious management guidance. Community sentiment is heavily polarized, with many retail investors expressing frustration over the persistent downtrend while active traders are aggressively positioning in LEAPs and accumulating common equity, betting on a technical bounce driven by the firm's core medical technology fundamentals.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy volume as traders debate the company's pivot toward becoming an AI infrastructure backbone through its Private Connectivity Fabric and recent strategic acquisitions. While bulls point to massive hyperscaler deal potential and a critical fiber footprint as long-term catalysts, the stock faces intense selling pressure from institutional shorting and concerns regarding balance sheet constraints and legacy business decline.

WorldFinancial

Investors are actively debating the future of World Liberty Financial ($WLFI.X) amid sharp criticism of its performance and vocal community accusations of a potential "rug pull" or grift tied to political branding. While some participants are aggressively calling for a rebound driven by anticipated token burns and supply shocks, others are heavily focused on the significant losses incurred and questioning the project's long-term legitimacy.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is gaining positive momentum as investors rotate toward stable, high-margin payment leaders, bolstered by new partnerships with platforms like Bridge to expand stablecoin-linked cards globally. Market participants are actively tracking the stock's consolidation near key support levels, anticipating that continued growth in digital commerce and cross-border volume will drive a technical breakout.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is experiencing significant market volatility surrounding its earnings report as investors weigh the company's Ibtrozi commercial launch against concerns over patient retention in late-line treatments. Community sentiment remains split between long-term optimism regarding a potential buyout catalyst and frustration over recent downward price pressure and insider trading activity.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. (PURR) is seeing a surge in retail interest driven by its correlation to the Hyperliquid ecosystem and a potential gamma squeeze setup, with market participants closely monitoring its upcoming Russell index inclusion. Investors are actively discussing the decoupling of its stock price from the HYPE token and the broader implications of its institutional-grade treasury strategy compared to other digital asset plays.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

Key PointsAccording to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026...

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced...

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE...

Why Is NUVB Stock Falling Today?

Equity

Nuvation Bio announced its intention to raise up to $230 million via a convertible senior notes offering.


Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Nuvation Bio Announces Proposed Convertible Senior Notes Offering Nuvation Bio Announces Proposed Convertible Senior Notes Offering PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on...

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Key PointsDirector Robert Mashal purchased 25,000 shares at a price of $4.73 per share on June 9, 2026...

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio to Present at the Jefferies Global Healthcare Conference Nuvation Bio to Present at the Jefferies Global Healthcare Conference PR Newswire NEW YORK, May 27, 2026 NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of...

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer...

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio to Collaborate with Thermo Fisher...

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NUVBNuvation Bio Inc - Ordinary Shares - Class A

Fundamentals

Latest NUVB News